DPP4 and diabetic kidney disease: In recent years, the application of sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors have largely improved the prognosis of DKD patients, therefore further studies are needed to investigate the outcomes between the two groups after treatment.